Abstract 850P
Background
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults. The origin can be found in chromosomal translocations as well as in accumulated mutations in genes involved in hematopoietic proliferation and differentiation. Despite being considered a heterogeneous malignancy, AML possesses many genetic aberrations, including the overexpression of MYC and the downregulation of PP2A, both essential regulators of cell proliferation, apoptosis, and differentiation, and they, directly and indirectly, regulate each other’s activity. We have generated a zebrafish model of MYC-driven AML to rapidly test the effects of different drugs in tumor development.
Methods
After the generation of a transgenic zebrafish line expressing the human MYC under the control of the neutrophils-specific promoter lysozyme (lyz:hMYC), we checked the expansion of neutrophils in whole larvae and the colonization of the adult hematopoietic organ. We investigated the effects of chemical manipulation of PP2A activity on neutrophil expansion and on MYC phosphorylation and degradation. Single-cell RNA sequencing analysis has been performed to shed light into the mechanisms of PP2A/proteasomal-mediated degradation of oncogenic MYC in AML.
Results
In vivo imaging of whole larvae revealed a robust expansion of neutrophils in zebrafish larvae which expressed MYC from 3 to 8 days post-fertilization (dpf). Surprisingly, the neutrophil number gradually returned to normal levels from 10 dpf onwards, coinciding with degradation of MYC. Pharmacological inhibition of the proteasome resulted in the stabilization of MYC protein and further expansion of transformed neutrophils. Similarly, inhibition of PP2A phenocopied the effects of proteasome inhibition. Otherwise, pharmacological activation of PP2A prevented neutrophil expansion and increased phosphorylation of S62 and T58 of MYC, suggesting a critical role PP2A in MYC proteasomal degradation.
Conclusions
Our results show that PP2A critically regulates MYC degradation in neutrophils preventing their oncogenic transformation. In addition, the zebrafish model of AML is a unique tool for chemical screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Murcia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18